Despite the huge promise of ADCs and their active clinical development worldwide, their effectiveness, ease of manufacturing and clinical potential has been limited by several factors, including the production of complex mixtures rather than ideally a single, pure, active constituent.
Significant gaps exist in the linker chemistry technology that allows the formation of ADCs. Most notably, non-specific methods for producing ADCs often lead to complicated mixtures having suboptimal safety and efficacy, and have been cumbersome and challenging to scale for manufacturing purposes.
To perfect ADC products and minimize labor intensive and costly manufacturing processes, as well as increase the odds for regulatory approvals, a linker technology that can attach to a specific site on an antibody must be developed. Advanced Proteome is currently advancing technology with broad applications and commercial potential to overcome some of the limitations of traditional ADCs.